

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Tan Aik Na</u>  (Last) (First) (Middle) C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE.  (Street) CAMBRIDGE MA 02138  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Wave Life Sciences Ltd. [ WVE ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 12/08/2025	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	12/08/2025		S <sup>(1)</sup>		7,494	D	\$12.75	32,894	D	
Ordinary Shares	12/08/2025		S <sup>(1)</sup>		7,494	D	\$15	25,400	D	
Ordinary Shares	12/08/2025		M <sup>(1)</sup>		32,230	A	\$5.37	57,630	D	
Ordinary Shares	12/08/2025		S <sup>(1)</sup>		15,000	D	\$12.75	42,630	D	
Ordinary Shares	12/08/2025		S <sup>(1)</sup>		17,230	D	\$15	25,400	D	
Ordinary Shares	12/08/2025		M <sup>(1)</sup>		45,000	A	\$4.585	70,400	D	
Ordinary Shares	12/08/2025		S <sup>(1)</sup>		20,000	D	\$12.75	50,400	D	
Ordinary Shares	12/08/2025		S <sup>(1)</sup>		25,000	D	\$15	25,400	D	
Ordinary Shares	12/08/2025		M <sup>(1)</sup>		21,000	A	\$3.5	46,400	D	
Ordinary Shares	12/08/2025		S <sup>(1)</sup>		21,000	D	\$12.75	25,400	D	
Ordinary Shares	12/08/2025		M <sup>(1)</sup>		21,000	A	\$5.97	46,400	D	
Ordinary Shares	12/08/2025		S <sup>(1)</sup>		21,000	D	\$12.75	25,400	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Share Option (right to buy)	\$5.37	12/08/2025		M <sup>(1)</sup>			32,230	(2)	08/12/2029	Ordinary Shares	32,230	\$0.00	0	D	
Share Option (right to buy)	\$4.585	12/08/2025		M <sup>(1)</sup>			45,000	(2)	08/07/2028	Ordinary Shares	45,000	\$0.00	0	D	
Share Option (right to buy)	\$3.5	12/08/2025		M <sup>(1)</sup>			21,000	(2)	08/15/2027	Ordinary Shares	21,000	\$0.00	0	D	
Share Option (right to buy)	\$5.97	12/08/2025		M <sup>(1)</sup>			21,000	(2)	08/16/2026	Ordinary Shares	21,000	\$0.00	0	D	

**Explanation of Responses:**

1. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.
2. These share options are fully vested.

/s/ Aik Na Tan

12/10/2025

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**